ASH Highlights - ALPINE Trial Shows Improved Efficacy and Safety Profile of Zanubrutinib vs Ibrutinib in CLL

IMPACT Medicom

Live From ASH, New Orleans:
In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
Our Guest:
Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.
This podcast episode was sponsored by BeiGene Canada ULC.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com